



Medical Compression System (D.B.N.) Ltd.

June 12, 2008

Israel Securities Authority
via MAGNA

Tel Aviv Stock Exchange Ltd.
via MAGNA

re: **Immediate report**

To whom it may concern,

Pursuant to the immediate reports of May 20, 2008 (reference: 2008-01-139104), March 17, 2008 (reference: 2008-01-073815) and October 2, 2007 (reference: 2008-01-406591), the Company is pleased to announce the end of the multi-center clinical trial, in which the Company's device was compared to the leading medication for Deep Vein Thrombosis (DVT) prevention in total hip replacement (Lovenox).

According to the report of the principal investigator, Dr. Colwell, the results of the trial conducted by the Company in the US demonstrate that prevention of DVT with the ActiveCare+S.F.T.® device manufactured by the Company is safer than prevention of DVT through the leading medication in this market (Lovenox) with similar effectiveness.

The Company believes that the completion of the trial and the final results substantiate its approach, according to which the Company's device can be used as alternative treatment, and is even preferable to treatment by medication. This is an important boost to the marketing potential of the product.

Company estimates regarding the potential impact of the results of the trial on its business results are forward-looking statements, as defined in the Securities Law, and there is no guarantee that said statements will materialize. Among other things, the Company's estimates are based on its familiarity with the relevant market. These estimates may not materialize, in whole or in part, or materialize materially differently than expected.

Sincerely,

Medical Compression System (D.B.N.) Ltd.

Medical Compression Systems (D.B.N) Ltd, 2 Ha'Ilan St, Or Akive, 30600
Tel: +972-4-626-6630, Fax: +972-4-626-6640
www.mcsmed.com